A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)

Baxalta now part of Shire0 sitesDecember 31, 2015

ConditionsImmunoglobulin A Nephropathy

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Immunoglobulin A Nephropathy
Sponsor: Baxalta now part of Shire
Primary Endpoint: Percent change in proteinuria from Baseline to Week 24
Status: Withdrawn
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)

Registry

clinicaltrials.gov

Start Date

December 31, 2015

End Date

November 30, 2016

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Baxalta now part of Shire

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•18 years of age or older at the time of screening
•Participant may be of any race or ethnicity
•Participant must have a biopsy-proven diagnosis of IgAN.
•Participant's blood pressure is ≤130/80 mmHg at Screening
•Participant is on maximally tolerated dose of an angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker (ARB) for at least 3 months prior to the baseline visit.
•Participant must present at screening with current proteinuria levels between 1 g/24 h and 3.5 g/24 h, based on spot urine protein-to-creatinine ratio (UPCR)
•Participant must present at screening with an estimated glomerular filtration rate (eGFR) \>40mL/min/1.73m\^2
•If a female of childbearing potential, participant must have a negative pregnancy test at screening, is not currently breastfeeding, and agrees to employ adequate birth control measures for the duration of the study. Male participants with female partners of childbearing potential must agree to use adequate birth control measures for the duration of the study
•Participant is willing and able to comply with the requirements of this protocol and agrees to sign an informed consent form prior to any study-related activities

Exclusion Criteria

•Participant has a history or current evidence of renal disease other than IgAN
•Participants with evidence of rapidly progressive disease
•Participant has IgAN with histologic evidence of advanced tubular atrophy and interstitial
•History or current evidence of other autoimmune disease
•History or current evidence of any chronic or uncontrolled medical condition which could, in the opinion of the Investigator, affect the participant's safety and ability to adhere to this protocol
•History or current evidence of a severe acute or chronic infection
•Use of systemic corticosteroids within 3 months prior to baseline, or anticipated use during the treatment period (Week 1 through Week 4). Note: Corticosteroids administered by inhalation or intranasally, or limited topical use of low-potency topical corticosteroids are allowed throughout the study.
•Known hypersensitivity or allergic reaction to any E. coli-derived recombinant product, yeast extract, or to the IP or any of its excipients
•Treatment with any immunomodulatory/immunosuppressive compound or monoclonal antibody for any indication within 6 months (unless otherwise stated) prior to screening (eg, B cell-depleting agents \[eg, rituximab, epratuzumab\] for ≥48 weeks; B-cell modifying agents \[eg, belimumab, atacicept\] for ≥24 weeks; IV immunoglobulins for ≥12 weeks and all other immunosuppressive treatments \[eg, methotrexate, cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine\] for ≥12 weeks)
•Clinically significant laboratory abnormalities prior to baseline

Outcomes

Primary Outcomes

Percent change in proteinuria from Baseline to Week 24

Time Frame: Baseline and Week 24

Secondary Outcomes

Number of infusions that had to be slowed, interrupted, or terminated due to adverse events (AEs) or serious adverse events (SAEs)(Throughout the study period of approximately 19 months)
Pharmacokinetics: time of maximum observed concentration (Cmax)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Number of participants who experience serious adverse events (SAEs) or adverse events (AEs)(Throughout the study period of approximately 19 months)
Number of participants with any clinically significant change in vital signs during investigational product (IP) administration or within 30 minutes following administration(Baseline through 30 minutes following IP administration)
Number of infusions associated with adverse events (AEs) or serious adverse events (SAEs) , regardless of causality(Throughout the study period of approximately 19 months)
Pharmacokinetics: maximum observed concentration (Cmax)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Clinically significant abnormal laboratory assessments(Throughout the study period of approximately 19 months)
Pharmacokinetics: volume of distribution at the terminal phase (Vz)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Number of participants who demonstrate a ≥30% reduction from Baseline in proteinuria(Baseline, Week 8, Week 12, Week 18, and Week 24)
Number of participants who experience any treatment-related serious adverse event (SAE) or severe adverse events (AE) during the course of the treatment period or subsequent follow-up period(Throughout the study period of approximately 19 months)
Number of participants who experience temporally-related adverse events (AEs)(Baseline through 72 hours of IP administration)
Number of participants who reach and maintain proteinuria levels below 1.0 g/24 h(Week 8, Week 12, Week 18, and Week 24)
Mean change from Baseline in Estimated glomerular filtration rate (eGFR)(Baseline, Week 8, Week 12, Week 18, and Week 24)
Number of participants with detectable levels of antidrug antibodies (ADAs)(Baseline, Week 3, Week 4, Week 12, Week 24, or early termination from the study)
Pharmacokinetics: terminal half-life (t1/2)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Pharmacokinetics: systemic clearance (CL)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Pharmacokinetics: volume of distribution at steady state (Vss)(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)
Pharmacokinetics: area under the concentration-time curve during a dosing interval (AUC(0-tau))(Week 1 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 8 or 12, 24, 48 or 72, and 168 hours. Week 4 within 30 minutes pre-infusion, and post-infusion 0.5, 1, 2, 4, 24, and 168 hours.)